Thursday, August 14, 2008

Immunosyn Corporation Files 10-Q

Last update: 11:23 a.m. EDT Aug. 14, 2008
LA JOLLA, Calif., Aug 14, 2008 (BUSINESS WIRE) -- Immunosyn Corporation (IMYN:
immunosyn corp com

Sponsored by:
IMYN 1.70, -0.10, -5.6%) , a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending June 30, 2008.

For the quarter ended June 30, 2008, the company incurred $629,884.00 in general and administrative expenses and $15,297.00 in interest expense which was funded from advances by affiliates of $26,527.00, accounts payable of $60,376.00, accrued expenses of ($1,498.00) and services rendered for stock of $529,250. As a result, the company had a Net Loss of $645,181.00 for the second quarter of 2008. During the same period in 2007, the company incurred $71,025.00 in general and administrative expenses, interest expense of $4,810.00 and had a Net Loss of $75,835.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.

"We have continued to significantly control costs this quarter and appreciated the advances from affiliates," noted Stephen Ferrone, Immunosyn's CEO. "In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC," added Ferrone.

Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating diabetic ulcers. Immunosyn went public in January 2007 and its stock began trading on October 26, 2007 on the OTCBB under the symbol "IMYN."

Sponsored by:
IMYN 1.70, -0.10, -5.6%) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements.

For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-KSB for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
SOURCE: Immunosyn Corporation

The Blaine Group
Lisa Baker/Devon Blaine
310-360-1498 (FAX)

Tuesday, August 5, 2008

Things To Ponder....

Hello Everyone,
I am going to share some of my favorite words to ponder on when I am feeling one way or another, but no way in particular....Hope you enjoy them.

Life is easier than you think --
All you have to do is:
Accept the impossible,
Do without the indispensable,
Bear the intolerable
Be able to smile at anything.


Acceptance is the answer to all my problems today.
When I am disturbed, it is because I find some person, place, thing, or situation --
Some fact of my life - unacceptable to me, and I can find no serenity until I accept that person, place, thing, or situation as being exactly the way it is supposed to be at this moment,
Nothing, absolutely nothing happens in God's wold by mistake.
Unless I accept life completely on life's terms, I cannot be happy.
I need to concentrate not so much on what needs to be changed in the world as on what needs to be changed in me and in my attitudes.


Only some of us learn by other people's mistakes; the rest of us have to be the other people.


True Understanding

We do not understand:
Joy......until we face sorrow
Faith....until it is tested
Peace....until faced with conflict
Trust....until we are betrayed
Love.....until it is lost
Hope.....until confronted with doubts.


Hope Makes A Difference

Hope looks for the good in people instead of harping on the worst in them.
Hope opens doors where despair closes them.
Hope discovers what can be done instead of grumbling about what cannot be done.
Hope draws its power from a deep trust in God and the basic goodness of mankind.
Hope "lights a candle" instead of "cursing the darkness."
Hope regards problems, small or large, as opportunities.
Hope cherishes no illusions, nor does it yield to cynicism.


And last, but by no means least.....

Thank You, dear God
For all You have given me
For all You have taken away from me
For all You have left me.


I hope you were able to get a nugget or two out of these, I know I sure have.